Episodes
-
In the sixth episode of The new frontier podcast, we're joined by Catherine Vrentas, Life Sciences Lead at Booz Allen Hamilton (VA, USA). Cathy explains how biomarkers can be used to predict the therapeutic outcome and efficacy of CGTs and the biomarkers in particular that have shown strong predictive value. We delve into the common challenges of working with biomarkers in CGTs and how biomarker kits can be adapted for CGT work.
-
Carlon Fitzpatrick AI Summit by Taylor & Francis Group
-
Episodes manquant?
-
We caught up with Principal Scientist Lindsay Denhoff (ICON; Dublin, Ireland) to discuss immunogenicity considerations for therapeutic proteins and the current analytical methodologies for detecting and characterizing anti-drug antibodies (ADAs). Lindsay shares some industry best practices for achieving high-quality ADA assays, as well as some of the advantages and limitations of singlicate ADA analysis compared with alternative techniques. We finish the interview with a look to the future where Lindsay discusses the emerging trends she's spotted in the field of immunogenicity and offers her predictions for how they may shape the future of therapeutic protein development.
-
In this Tech Blast episode supported by Sartorius (Göttingen, Germany), we speak with David Apiyo – Manager of Applications Development at Sartorius (MN, USA) – about epitope binning, why it's performed and the best ways to conduct it. Plus, learn more about Sartorius' biolayer interferometry platforms and their application in epitope binning.
-
In this interview, we spoke to John Chappell, Senior Global Scientific Support Manager at Gyros Protein Technologies (Uppsala, Sweden) about his experience working with the Gyrolab platform for oligonucleotide assays. John discusses the advantages of using Gyrolab for oligo quantification in biological fluids and shares his thoughts on the next steps for these assays.
-
In the fifth episode of The New Frontier podcast, we're joined by Paul Byrne, Senior Director of Genomics from ProtaGene (MA, USA). Paul describes his experience working with qPCR vs digital and digital droplet PCR assays and advises on their pros and cons, as well as when it's best to use each. We discuss how these assays can be optimized for cell and gene therapy targets and get a peek into the tips and tricks he's picked up over his 30 years of experience.
-
In this episode of The New Frontier podcast, we're joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel explains how he uses immune-precipitation and immunoaffinity LC–MS techniques for his work relating to macromolecular pharmaceuticals like gene therapies, as well as their benefits and challenges. Daniel also covers bottom-up, middle-down and top-down approaches and their suitability for his work in clinical support versus research and discovery.
-
Breaking down barriers for women in tech: an interview with Tina Marshall by Taylor & Francis Group
-
What disparities exist in cancer screening and how does this impact patient outcomes? Listen to our latest podcast episode with Kilan Ashad-Bishop (American Cancer Society) to find out about the intersection between science, health, and society.
-
AI-driven early disease detection: an interview with Jim Kean by Taylor & Francis Group
-
In this episode, we spoke to Senior Director Johanna Mora about her experience with immunogenicity testing for cell and gene therapies (CGTs) and how she prepared for the expansion of BMS's portfolio to include CGTs. We discuss the importance of having diverse teams with a broad range of experiences to solve complex problems, as well as the role of artificial intelligence in improving our efficiency and spotting patterns in the data.
-
In the first episode of this series, we spoke to Executive Director and Global Head of Regulatory Services Kimberley Buytaert-Hoefen about her experience with cell and gene therapy (CGT) approvals and the barriers to getting these important therapeutics to the patient. Kim advises early regulatory interaction and collaboration to improve the success rate of applications and emphasizes the importance of global harmonization of regulatory standards. We discuss key barriers to CGT approvals including manufacturing and immunogenicity and Kim voices her excitement for the newly approved CRISPR-Cas9 technology to treat sickle cell disease.
-
AI and the UK Biobank: an interview with Mahesh Pancholi
-
In our new podcast series, we're joined by a Bioanalysis author to review their publication's biggest challenges, wider implications and next steps. In the final episode of series one, we're joined by Hetal Sarvaiya and Yuting Wang from AbbVie (MA, USA), who talk about the challenges of having an international team working on their perspective article and the inspiration behind their work. The pair talk passionately about their paper and how the unique nature of AbbVie's global team has helped shape their work.
-
Virtual reality therapies for mental health: Marta Matamala-Gomez
-
An interview with Namshik Han: predicting protein structure with AI
-
In this Tech Blast episode supported by Sartorius, we speak with Derrick Christopher Campos, Product Manager at Sartorius (TX, USA), about Surface Plasmon Resonance (SPR). This tried-and-true technique allows researchers to do label-free protein characterization; in this podcast, Derrick discusses how Sartorius improves upon multi-cycle kinetics with their OneStep® gradient injection.
-
In our new podcast series, we're joined by a Bioanalysis author to review their publication's biggest challenges, wider implications and next steps. In episode four, we're joined by Senior Scientist and Technical Specialist Ashley Phillips. Ashley's publication assessed the performance of next-generation trypsins for rapid protein LC-MS bioanalysis, effectively reducing a two-day process into just one day's work. As the paper's lead author, Ashley outlines the experimental design, the challenges associated with data storage and how he and the team are now applying the best-performing trypsin in their workflows.
-
In our new podcast series, we're joined by a Bioanalysis author to review their publication's biggest challenges, wider implications and next steps. In episode three, Digital Editor Ellen Williams is joined by Clinical Instructor and Education Coordinator Camilla Linder and Biomedical Laboratory Scientist Miguel Gambell Barroso. The collaborative publication details an inventive method for determining hematocrit in dried blood spots using image analysis to avoid sample damage. Camilla and Miguel discuss the origins of the work, the challenges involved and even hint at a unique use for their method.
- Montre plus
